TAT-BH3 methods for treating arthritis
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 22, 2014
Issued Date -
N/A
app pub date -
Feb 14, 2008
filing date -
Feb 14, 2007
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention is directed to compositions and methods for treating immune system mediated disease. In particular, certain embodiments of the present invention use BH3 mimetic therapy as an efficacious treatment of the effector phase of RA wherein the compositions and methods of the present invention markedly reduce the level of the Bcl-2 antagonist protein Bim present in RA synovial tissue as compared to control patients. Therefore, the present invention involves restoring the function of Bim in order to ameliorate inflammatory arthritis. In connection therewith, systemic delivery of a peptide to the BH3 domain of Bim effectively inhibits the development of K/B×N serum transfer-induced arthritis which closely resembles the effector phase of RA.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully